Objective: To examine the effect of letrozole on symptomatic leiomyomata. Patients and Methods: In a prospective, intervention study , forty six premenopausal women with fifty two leiomyomata were invited to take 5 mg letrozole daily for 3 treatment cycles of 28 days each. Leiomyoma, uterine and ovarian volumes, endometrial thickness, gonadotrophins, and the scores of menstrual pictograms and Uterine Fibroid Symptom and Health Related Quality of Life (UFS – HRQoL) were recorded at the start and conclusion of this study. Results: Letrozole resulted in 53.29% mean reduction in original leiomyomata volumes (P < 0.01) without significant reduction in myoma free uterine tissue. Estradiol levels dropped significantly from baseline levels (64.32 + 16.77) (mean + SD) to (40.83 + 12.032) pg/ml (p < 0.001) at the end of this study. Conclusion: Adding to its significant shrinkage of leiomyomta, letrozole improved leiomyoma related symptomology, quality of life and menstrual pattern significantly.
Ghal, H. A. (2011). Aromastase Inhibitor Therapy For Symptomatic Uterine Leimyomata In Premenopausal Women. The Egyptian Journal of Fertility and Sterility, 15(2), 29-33. doi: 10.21608/egyfs.2011.257273
MLA
Hanan A.A Ghal. "Aromastase Inhibitor Therapy For Symptomatic Uterine Leimyomata In Premenopausal Women", The Egyptian Journal of Fertility and Sterility, 15, 2, 2011, 29-33. doi: 10.21608/egyfs.2011.257273
HARVARD
Ghal, H. A. (2011). 'Aromastase Inhibitor Therapy For Symptomatic Uterine Leimyomata In Premenopausal Women', The Egyptian Journal of Fertility and Sterility, 15(2), pp. 29-33. doi: 10.21608/egyfs.2011.257273
VANCOUVER
Ghal, H. A. Aromastase Inhibitor Therapy For Symptomatic Uterine Leimyomata In Premenopausal Women. The Egyptian Journal of Fertility and Sterility, 2011; 15(2): 29-33. doi: 10.21608/egyfs.2011.257273
)
View on SCiNiTO